Hypoxia makes EZH2 inhibitor not easy—advances of crosstalk between HIF and EZH2

Abstract

Histone methylation plays a crucial role in tumorigenesis. Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase that regulates chromatin structure and gene expression. EZH2 inhibitors (EZH2is) have been shown to be effective in treating hematologic malignancies, while their effectiveness in solid tumors remains limited. One of the major challenges in the treatment of solid tumors is their hypoxic tumor microenvironment. Hypoxia-inducible factor 1-alpha (HIF-1α) is a key hypoxia responder that interacts with EZH2 to promote tumor progression. Here we discuss the implications of the relationship between EZH2 and hypoxia for expanding the application of EZH2is in solid tumors.

Keywords

EZH2 / HIF-1α / hypoxia / nanoparticles / TCA cycle / drug combination

References

[1] Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov 2022;12:31–46.

[2] Cavalli G, Heard E. Advances in epigenetics link genetics to theenvironment and disease. Nature 2019;571:489–99.

[3] Yamagishi M, Kuze Y, Kobayashi S et al. Mechanisms of actionand resistance in histone methylation-targeted therapy. Nature 2024;627:221–8.

[4] Gui T, Liu M, Yao B et al. TCF3 is epigenetically silenced by EZH2and DNMT3B and functions as a tumor suppressor in endometrial cancer. Cell Death Differ 2021;28:3316–28.

[5] Kim KH, Roberts CW. Targeting EZH2 in cancer. Nat Med 2016;22:128–34.

[6] Kleer CG, Cao Q, Varambally S et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation ofbreast epithelial cells. Proc Natl Acad Sci U S A 2003;100:11606–11.

[7] Burr ML, Sparbier CE, Chan KL et al. An evolutionarily conserved function of polycomb silences the MHC Class I antigen presentation pathway and enables immune evasion in cancer. CancerCell 2019;36:385–401.e8.

[8] Davies A, Nouruzi S, Ganguli D et al. An androgen receptorswitch underlies lineage infidelity in treatment-resistant prostate cancer. Nat Cell Biol 2021;23:1023–34.

[9] Makita S, Tobinai K. Targeting EZH2 with tazemetostat. LancetOncol 2018;19:586–7.

[10] Gounder M, Schöffski P, Jones RL et al. Tazemetostat inadvanced epithelioid sarcoma with loss of INI1/SMARCB1: aninternational, open-label, phase 2 basket study. Lancet Oncol 2020;21:1423–32.

[11] Cohen PA, Jhingran A, Oaknin A et al. Cervical cancer. Lancet 2019;393:169–82.

[12] Kam AE, Masood A, Shroff RT. Current and emerging therapiesfor advanced biliary tract cancers. Lancet Gastroenterol Hepatol 2021;6:956–69.

[13] Bai R, Li Y, Jian L et al. The hypoxia-driven crosstalk betweentumor and tumor-associated macrophages: mechanisms andclinical treatment strategies. Mol Cancer 2022;21:177.

[14] Fukumura D, Kloepper J, Amoozgar Z et al. Enhancing cancerimmunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol 2018;15:325–40.

[15] Huang Y, Kim BYS, Chan CK et al. Improving immune-vascular crosstalk for cancer immunotherapy. Nat Rev Immunol 2018;18:195–203.

[16] Verginadis II, Avgousti H, Monslow J et al. A stromal integratedstress response activates perivascular cancer-associated fibroblasts to drive angiogenesis and tumour progression. Nat CellBiol 2022;24:940–53.

[17] Chen J, Liu G, Wang X et al. Glioblastoma stem cell-specific histamine secretion drives pro-angiogenic tumor microenvironmentremodeling. Cell stem cell 2022;29:1531–46.e7.

[18] Wang X, Chen Z, Xu J et al. SLC1A1-mediated cellular and mitochondrial influx of R-2-hydroxyglutarate in vascular endothelial cells promotes tumor angiogenesis in IDH1-mutant solidtumors. Cell Res 2022;32:638–58.

[19] Zhang L, Xu J, Zhou S et al. Endothelial DGKG promotes tumorangiogenesis and immune evasion in hepatocellular carcinoma. J Hepatol 2024;80:82–98.

[20] Ortmann BM, Burrows N, Lobb IT et al. The HIF complex recruits the histone methyltransferase SET1B to activate specific hypoxia-inducible genes. Nat Genet 2021;53:1022–35.

[21] Méndez-Blanco C, Fondevila F, García-Palomo A et al. Sorafenibresistance in hepatocarcinoma: role of hypoxia-inducible factors. Exp Mol Med 2018;50:1–9.

[22] Chen Y, Zhang J, Zhang M et al. Baicalein resensitizes tamoxifen-resistant breast cancer cells by reducing aerobic glycolysis andreversing mitochondrial dysfunction via inhibition of hypoxia-inducible factor-1α. Clin Transl Med 2021;11:e577.

[23] Wang D, Zhao C, Xu F et al. Cisplatin-resistant NSCLC cellsinduced by hypoxia transmit resistance to sensitive cellsthrough exosomal PKM2. Theranostics 2021;11:2860–75.

[24] Hwang-Verslues WW, Chang PH, Jeng YM et al. Loss of corepressor PER2 under hypoxia up-regulates OCT1-mediated EMT gene expression and enhances tumor malignancy. Proc Natl Acad SciU S A 2013;110:12331–6.

[25] Chi Y, Xin H, Liu Z. Exosomal lncRNA UCA1 derived from pancreatic stellate cells promotes gemcitabine resistance in pancreatic cancer via the SOCS3/EZH2 axis. Front Oncol 2021;11:671082.

[26] Pan M, Reid MA, Lowman XH et al. Regional glutamine deficiency in tumours promotes dedifferentiation through inhibition of histone demethylation. Nat Cell Biol 2016;18:1090–101.

[27] Eid RA, Alkhateeb MA, Eleawa S et al. Cardioprotective effect ofghrelin against myocardial infarction-induced left ventricularinjury via inhibition of SOCS3 and activation of JAK2/STAT3 signaling. Basic Res Cardiol 2018;113:13.

[28] Zeng F, Zhang Y, Han X et al. Employing hypoxia characterization to predict tumour immune microenvironment, treatmentsensitivity and prognosis in hepatocellular carcinoma. ComputStruct Biotechnol J 2021;19:2775–89.

[29] Ngule CM, Hemati H, Ren X et al. Identification of a NACC1-regulated gene signature implicated in the features of triple-negative breast cancer. Biomedicines 2023;11:1223.

[30] Li X, Xing J, Wang H et al. The SLC34A2-ROS-HIF-1-inducedup-regulation of EZH2 expression promotes proliferation andchemo-resistance to apoptosis in colorectal cancer. Biosci Rep 2019;39:BSR20180268.

[31] Shan L, Zhou X, Liu X et al. FOXK2 elicits massive transcriptionrepression and suppresses the hypoxic response and breastcancer carcinogenesis. Cancer Cell 2016;30:708–22.

[32] Cao P, Deng Z, Wan M et al. microRNA-101 negatively regulatesEzh2 and its expression is modulated by androgen receptor and HIF-1α/HIF-1β. Mol Cancer 2010;9:108.

[33] Wang X, Wang Y, Li L et al. A lncRNA coordinates with Ezh2 toinhibit HIF-1α transcription and suppress cancer cell adaptionto hypoxia. Oncogene 2020;39:1860–74.

[34] Kim TW, Lee HG. Apigenin induces autophagy and cell death bytargeting EZH2 under hypoxia conditions in gastric cancer cells. Int J Mol Sci 2021;22:13455.

[35] Wang J, Yang C, Xu H et al. The interplay between HIF-1α and EZH2 in lung cancer and dual-targeted drug therapy. Adv Sci(Weinh) 2024;11:e2303904.

[36] Pang B, Zheng XR, Tian JX et al. EZH2 promotes metabolic reprogramming in glioblastomas through epigenetic repression ofEAF2-HIF1α signaling. Oncotarget 2016;7:45134–43.

[37] Sun CC, Zhu W, Li SJ et al. FOXC1-mediated LINC00301 facilitates tumor progression and triggers an immune-suppressingmicroenvironment in non-small cell lung cancer by regulatingthe HIF1α pathway. Genome Med 2020;12:77.

[38] Zhao Y, Wang XX, Wu W et al. EZH2 regulates PD-L1 expressionvia HIF-1α in non-small cell lung cancer cells. Biochem BiophysRes Commun 2019;517:201–9.

[39] Saggese P, Pandey A, Alcaraz M et al. Glucose deprivation promotes pseudo-hypoxia and de-differentiation in lung adenocarcinoma. Cancer Res 2024;84:305–27.

[40] Michealraj KA, Kumar SA, Kim LJY et al. Metabolic regulationof the epigenome drives lethal infantile ependymoma. Cell 2020;181:1329–45.e24.

[41] Chang CJ, Yang JY, Xia W et al. EZH2 promotes expansion ofbreast tumor initiating cells through activation of RAF1-β-catenin signaling. Cancer Cell 2011;19:86–100.

[42] Hu L, Zeng Y, Xin L et al. SND1, a novel co-activator of HIF1α promotes tumor initiation in PyMT-induced breast tumor. FEBS J 2023;290:5759–72.

[43] Chen S, Chen JZ, Zhang JQ et al. Hypoxia induces TWIST-activated epithelial-mesenchymal transition and proliferationof pancreatic cancer cells in vitro and in nude mice. Cancer Lett 2016;383:73–84.

[44] Mahara S, Lee PL, Feng M et al. HIFI-α activation underlies afunctional switch in the paradoxical role of Ezh2/PRC2 in breast cancer. Proc Natl Acad Sci U S A 2016;113:E3735–44.

[45] Tang B, Sun R, Wang D et al. ZMYND8 preferentially binds phosphorylated EZH2 to promote a PRC2-dependent to -independent function switch in hypoxia-inducible factor-activated cancer. Proc Natl Acad Sci U S A 2021;118:e2019052118.

[46] Mohammadi Ghahhari N, Sznurkowska MK, Hulo N et al. Cooperative interaction between ERα and the EMT-inducerZEB1 reprograms breast cancer cells for bone metastasis. NatCommun 2022;13:2104.

[47] Zhou H, Wu G, Ma X et al. Attenuation of TGFBR2 expression and tumour progression in prostate cancer involve diverse hypoxia-regulated pathways. J Exp Clin Cancer Res 2018;37:89.

[48] Zhou J, Lin Y, Kang X et al. Hypoxia-mediated promotion ofglucose metabolism in non-small cell lung cancer correlateswith activation of the EZH2/FBXL7/PFKFB4 axis. Cell Death Dis 2023;14:326.

[49] Jiang SS, Xie YL, Xiao XY et al. Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer. Cell Host Microbe 2023;31:781–97.e9.

[50] Selak MA, Armour SM, MacKenzie ED et al. Succinate links TCAcycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase. Cancer Cell 2005;7:77–85.

[51] Martínez-Reyes I, Chandel NS. Mitochondrial TCA cycle metabolites control physiology and disease. Nat Commun 2020;11:102.

[52] Chang PH, Chen MC, Tsai YP et al. Interplay between desmoglein2 and hypoxia controls metastasis in breast cancer. ProcNatl Acad Sci U S A 2021;118:e2014408118.

[53] Zhu S, Deng S, He C et al. Reciprocal loop of hypoxia-induciblefactor-1α (HIF-1α) and metastasis-associated protein 2 (MTA2) contributes to the progression of pancreatic carcinoma by suppressing E-cadherin transcription. J Pathol 2018;245:349–60.

[54] Wei FZ, Cao Z, Wang X et al. Epigenetic regulation of autophagyby the methyltransferase EZH2 through an MTOR-dependent pathway. Autophagy 2015;11:2309–22.

[55] Dodd KM, Yang J, Shen MH et al. mTORC1 drives HIF-1α and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3. Oncogene 2015;34:2239–50.

[56] Ren Z, Hu Y, Li G et al. HIF-1α induced long noncoding RNA FOXD2-AS1 promotes the osteosarcoma through repressing p21. Biomed Pharmacother 2019;117:109104.

[57] Riquelme E, Suraokar M, Behrens C et al. VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapy. Clin Cancer Res 2014;20:3849–61.

[58] Anwar T, Arellano-Garcia C, Ropa J et al. p38-mediated phosphorylation at T367 induces EZH2 cytoplasmic localization topromote breast cancer metastasis. Nat Commun 2018;9:2801.

[59] Gonzalez ME, Moore HM, Li X et al. EZH2 expands breast stemcells through activation of NOTCH1 signaling. Proc Natl Acad SciU S A 2014;111:3098–103.

[60] Wang HJ, Pochampalli M, Wang LY et al. KDM8/JMJD5 as a dualcoactivator of AR and PKM2 integrates AR/EZH2 network andtumor metabolism in CRPC. Oncogene 2019;38:17–32.

[61] Roy S, Huang B, Sinha N et al. Androgens regulate ovarian geneexpression by balancing Ezh2-Jmjd3 mediated H3K27me3 dynamics. PLoS Genet 2021;17:e1009483.

[62] Duan R, Du W, Guo W. EZH2: a novel target for cancer treatment. J Hematol Oncol 2020;13:104.

[63] Italiano A, Soria JC, Toulmonde M et al. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncol 2018;19:649–59.

[64] Youmans DT, Schmidt JC, Cech TR. Live-cell imaging revealsthe dynamics of PRC2 and recruitment to chromatin by SUZ12-associated subunits. Genes Dev 2018;32:794–805.

[65] Guo Y, Cheng R, Wang Y et al. Regulation of EZH2 protein stability: new mechanisms, roles in tumorigenesis, and roads to theclinic. EBioMedicine 2024;100:104972.

[66] Wang J, Yu X, Gong W et al. EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis. Nat Cell Biol 2022;24:384–99.

[67] Kuser-Abali G, Zhang Y, Szeto P et al. UHRF1/UBE2L6/UBR4-mediated ubiquitination regulates EZH2 abundance andthereby melanocytic differentiation phenotypes in melanoma. Oncogene 2023;42:1360–73.

[68] Cheng SC, Quintin J, Cramer RA et al. mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trainedimmunity. Science (New York, NY) 2014;345:1250684.

[69] Greenberger LM, Horak ID, Filpula D et al. A RNA antagonistof hypoxia-inducible factor-1α EZN-2968, inhibits tumor cell growth. Mol Cancer Ther 2008;7:3598–608.

[70] Onnis B, Rapisarda A, Melillo G. Development of HIF-1 inhibitors for cancer therapy. J Cell Mol Med 2009;13:2780–6.

[71] Rapisarda A, Uranchimeg B, Sordet O et al. TopoisomeraseI-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res 2004;64:1475–82.

[72] Zhang H, Qian DZ, Tan YS et al. Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth. Proc Natl Acad Sci U S A 2008;105:19579–86.

[73] Mabjeesh NJ, Escuin D, LaVallee TM et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003;3:363–75.

[74] Lian G, Li X, Zhang L et al. Macrophage metabolic reprogramming aggravates aortic dissection through the HIF1α-ADAM17 pathway. EBioMedicine 2019;49:291–304.

[75] Zhang Y, Zhou L, Safran H et al. EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG. Neoplasia 2021;23:792–810.

[76] Ong LT, Lee WC, Ma S et al. IFI16-dependent STING signaling is a crucial regulator of anti-HER2 immune response in HER2⁺ breast cancer. Proc Natl Acad Sci U S A 2022;119:e2201376119.

[77] Bao B, Ahmad A, Kong D et al. Hypoxia induced aggressiveness of prostate cancer cells is linked with deregulated expression of VEGF, IL-6 and miRNAs that are attenuated by CDF. PLoS One 2012;7:e43726.

[78] Liao Q, He H, Mao Y et al. Engineering T cells with hypoxia-inducible chimeric antigen receptor (HiCAR) for selective tumor killing. Biomark Res 2020;8:56.

[79] Zhang C, Pu K. Molecular and nanoengineering approaches towards activatable cancer immunotherapy. Chem Soc Rev 2020;49:4234–53.

[80] Zhang C, Zhao K, Bu W et al. Marriage of scintillator and semiconductor for synchronous radiotherapy and deep photodynamic therapy with diminished oxygen dependence. AngewChem Int Ed Engl 2015;54:1770–4.

[81] Zhu X, Guo X, Liu D et al. Promotion of propranolol deliveryto hemangiomas by using anti-VEGFR antibody-conjugated poly(lactic-co-glycolic acid) nanoparticles. J Biomed Nanotechnol 2017;13:1694–705.

[82] Lee HY, Kim HW, Lee JH et al. Controlling oxygen release fromhollow microparticles for prolonged cell survival under hypoxic environment. Biomaterials 2015;53:583–91.

[83] Song G, Ji C, Liang C et al. TaOx decorated perfluorocarbon nanodroplets as oxygen reservoirs to overcome tumor hypoxia and enhance cancer radiotherapy. Biomaterials 2017;112:257–63.

[84] Zhang S, Li Z, Wang Q et al. An NIR-II photothermally triggered “oxygen bomb” for hypoxic tumor programmed cascade therapy. Adv Mater 2022;34:e2201978.

[85] Song M, Liu T, Shi C et al. Bioconjugated manganese dioxide nanoparticles enhance chemotherapy response by priming tumor-associated macrophages toward M1-like phenotype and attenuating tumor hypoxia. ACS Nano 2016;10:633–47.

[86] Liu Y, Yang J, Liu B et al. Human iPS cells loaded with MnO₂-based nanoprobes for photodynamic and simultaneous enhanced immunotherapy against cancer. Nanomicro Lett 2020;12:127.

[87] Yang G, Xu L, Chao Y et al. Hollow MnO₂ as a tumor-microenvironment-responsive biodegradable nano-platformfor combination therapy favoring antitumor immune responses. Nat Commun 2017;8:902.

[88] Pan X, Wang W, Huang Z et al. MOF-derived double-layer hollownanoparticles with oxygen generation ability for multimodal imaging-guided sonodynamic therapy. Angew Chem Int Ed Engl 2020;59:13557–61.

[89] Xu B, Cui Y, Wang W et al. Immunomodulation-enhancednanozyme-based tumor catalytic therapy. Adv Mater 2020;32:e2003563.

[90] Li S, Shang L, Xu B et al. A nanozyme with photo-enhanced dual enzyme-like activities for deep pancreatic cancer therapy. Angew Chem Int Ed Engl 2019;58:12624–31.

[91] Li S, Xu B, Lu M et al. Tensile-strained palladium nanosheets for synthetic catalytic therapy and phototherapy. Adv Mater 2022;34:e2202609.

[92] Yang H, Xu B, Li S et al. A photoresponsive nanozyme for synergistic catalytic therapy and dual phototherapy. Small 2021;17:e2007090.

[93] Huang X, Zhuang J, Chung SW et al. Hypoxia-tropic protein nanocages for modulation of tumor- and chemotherapy-associated hypoxia. ACS Nano 2019;13:236–47.

[94] Gao F, Wu J, Gao H et al. Hypoxia-tropic nanozymes as oxygen generators for tumor-favoring theranostics. Biomaterials 2020;230:119635.

[95] Zhao Z, Dong S, Liu Y et al. Tumor microenvironment-activable manganese-boosted catalytic immunotherapy combined with PD-1 checkpoint blockade. ACS Nano 2022;16:20400–18.

[96] Shi J, Kantoff PW, Wooster R et al. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer 2017;17:20–37.

[97] Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986;46:6387–92.

[98] Sun X, Hong Y, Gong Y et al. Bioengineered ferritin nanocarriers for cancer therapy. Int J Mol Sci 2021;22:7023.

[99] Choi SY, Lin D, Gout PW et al. Lessons from patient-derived xenografts for better in vitro modeling of human cancer. Adv Drug Deliv Rev 2014;79-80:222–37.

[100] Liu OH, Kiema M, Beter M et al. Hypoxia-mediated regulation of histone demethylases affects angiogenesis-associated functions in endothelial cells. Arterioscler Thromb Vasc Biol 2020;40:2665–77.

RIGHTS & PERMISSIONS

The Author(s) 2024. Published by Oxford University Press on behalf of Higher Education Press.